RJFSA
ABEO icon

Raymond James Financial Services Advisors’s Abeona Therapeutics ABEO Stock Holding History

Raymond James Financial Services Advisors’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,580
Closed -$1.15M – 2567
2018
Q3 		$1.15M Buy
+3,580
New +$1.27M 0.01% 1385

Other funds holding ABEO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Raymond James Financial Services Advisors's ABEO Position: Q4 2018 in Review

Raymond James Financial Services Advisors sold out of Abeona Therapeutics (ABEO) in Q4 2018, closing a stake of 3,580 shares — an estimated $1.15M sold.

Raymond James Financial Services Advisors first reported a position in ABEO in Q3 2018 and held it in 1 quarter. The position peaked at $1.15M in Q3 2018. 99 funds tracked by Wall St. Rank hold ABEO as of Q4 2018.

  • Raymond James Financial Services Advisors reported no remaining Abeona Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 3,580 Abeona Therapeutics shares in Q4 2018, an estimated $1.15M.
  • Raymond James Financial Services Advisors first reported a position in Abeona Therapeutics in Q3 2018 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Abeona Therapeutics position peaked at $1.15M in Q3 2018.
  • 99 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q4 2018.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2018, filed 11 Feb 2019.